Antibody Drug Conjugate (ADC) Market Size, Share Global Analysis Report, 2023 – 2030

Industry Insights

[207+ Pages Report] According to Facts and Factors, the global antibody-drug conjugate (ADC) market size was valued at USD 9.25 billion in 2022 and is likely to surpass USD 20.51 billion by the end of 2030. The antibody-drug conjugate (ADC) industry is expected to grow with a CAGR of 10.53% during the forecast period.

Market Overview

Antibody-drug conjugate (ADC) is a type of targeted cell therapy that contains three components, namely, a cytotoxic drug, a linker molecule, and a monoclonal antibody. The major purpose of these drugs is to deliver the cytotoxic drug to a particular cancer cell site without affecting healthy cells, which helps minimize the side effects of the drugs and thereby improve its therapeutic effect.

Key Insights

• As per the analysis shared by our research analyst, the global antibody-drug conjugate (ADC) market size is estimated to grow annually at a CAGR of around 10.53% over the forecast period (2023-2030).
• In terms of revenue, the global antibody-drug conjugate (ADC) market size was valued at around USD 9.25 billion in 2022 and is projected to reach USD 20.51 billion by 2030.
• Advancement in antibody technology is driving the growth of the global antibody-drug conjugate (ADC) market.
• Based on the end users, the hospital & specialty cancer centers segment is growing at a high rate and is projected to dominate the global market.
• Based on the products, the Kadcyla ADC segment is projected to swipe the largest market share.
• Based on the applications, the breast cancer segment is the fastest-growing segment in the global market.
• Based on the target types, the HER2 Antibodies segment is anticipated to grow with a high CAGR in the global market.
• Based on the technology, the non-leviable linker segment is projected to swipe the largest market share.
• Based on region, North America is expected to dominate the global market during the forecast period.           

Growth Drivers

• Advancement in antibody technology is expected to boost the growth of the global market.

The increasing advancements in antibody engineering and technology have significantly accentuated the demand for ADCs in the global antibody-drug conjugate (ADC) market. These advancements have led to the development of more potent antibodies, which have significantly enhanced the efficacy and precision of these therapies.

Also, this increasing incidence of various types of cancer all across the globe is boosting the need for targeted cancer therapies. The hectic and sedentary lifestyle of people further contributes immensely to the increasing cancer risk. As a result, people are looking forward to the advanced treatment of cancer globally.

For instance, AvantGen and Adcentrx Therapeutics collaborated for three years with the goal of discovering antibodies. These antibodies are said to be developed into novel antibody drugs for the benefit of the patients.

Restraints

• High development costs are likely to restrain the growth of the global market.

The development of antibody-drug conjugate is quite expensive. It requires intensive processes like research, development, clinical trials, and finished manufacturing, which pose a demand for proper tech infrastructure. Such a landscape is likely to create barriers, particularly for start-ups and small biotech companies in the antibody-drug conjugate industry.

Opportunities

• Growing product pipeline and increasing collaborations are expected to foster growth opportunities in the global market.

The development of antibody-drug conjugate has significantly strengthened the product pipeline. This pipeline is likely to widen the scope of the antibody-drug conjugate (ADC) industry as companies will move towards the commercialization of these products after successful clinical trials.

Furthermore, many biotech and pharmaceutical companies are adopting collaborations and partnerships to strengthen their manufacturing, research, and development processes. The collaboration is also likely to expedite the development of a disease, which will further foster growth opportunities in the industry.

For instance, DualityBio and BeiGene collaborated to acquire an exclusive option for global clinical and commercial licenses for patients with said solid tumors.

Challenges

• Safety concerns and regulatory hurdles are a big challenge in the global market.

Anti-drug conjugates are very potent drugs which are said to contain certain toxicities. Therefore, balancing these drugs' therapeutic effects along with their side effects on the human body is a big challenge for manufacturers in the antibody-drug conjugate market. Also, regulatory approval in such a landscape is quite difficult and time-consuming. Therefore, the strict regulatory processes are likely to slow down the growth trajectory of the global market.

Segmentation Analysis

The global antibody-drug conjugate (ADC) market can be segmented into end users, products, applications, target types, technology, and regions.

By end users, the market can be segmented into biotechnology & pharmaceutical companies, hospitals & specialty cancer centers, and others. The hospital & specialty cancer centers segment accounts for the largest share of the antibody-drug conjugate (ADC) industry. These centers serve as a primary location for administering anti-conjugate therapies. These facilities are well equipped with specialized equipment to offer cancer treatment, including chemotherapy, ADCs, and others.

Also, the clinical trials for the anti-drug conjugate are conducted in these centers in collaboration with research institutes. The hospitals and specialized centers have the expertise and required infrastructure for clinical research. Therefore, such a landscape is expected to foster developments in the segment.

Moreover, patients perceive these centers as the hub for the best healthcare delivery. Patients are able to get their treatment plans from scratch and these services are accessible to a wider range of patients, which is another major reason propelling the growth of the segment.

By product, the market can be segmented into Kadcyla, Adcetris, and others. Kadcyla ADC is the fastest-growing segment in the global antibody-drug conjugate market. It is a well-known antibody-drug conjugate approved for the treatment of certain specific cancers. It is used in the treatment of HER2-positive breast cancer.

The positive clinical trial results for this drug have significantly increased the confidence of healthcare professionals and pharmaceutical companies, which has led to the greater adoption of this drug in the treatment of cancer patients. Moreover, the competitive landscape, increasing partnerships, and pricing strategies are likely to positively influence the growth of this drug in the global marketplace.

By application, the market can be segmented into brain tumors, skin cancer, lung cancer, ovary cancer, breast cancer, blood cancer, and others. The breast cancer segment is likely to dominate the growth of the antibody-drug conjugate industry. Breast cancer is a severe medical concern that requires innovative and effective therapies like ADCs for its treatment.

Breast cancer is among the most common cancers globally. Its high prevalence has significantly boosted the growth of the industry. Pharmaceutical companies and governments have also increased the research and development activities in the field of breast cancer treatment. The development of novel drugs for its treatment is likely to contribute heavily towards the growth of the segment.

By target type, the market can be segmented into HER2 Antibodies, CD30 Antibodies, and others. The HER2 Antibodies segment is projected to witness notable growth in the coming years. It is a wider area of interest in the field of oncology. The HER2 Antibodies segment refers to a protein that is over-expressed in the treatment of cancer, making it a crucial target for therapy. Moreover, the increasing incidences of breast cancer are propelling the scope of HER2 antibodies.

By technology, the market can be segmented into non-cleavable linkers and cleavable linkers. The non-leviable linker segment is expected to swipe the largest share of the global market. These linkers are stable and do not break down in the body easily, which is a core reason for their high popularity. These linkers are designed to keep the drug attached to the antibody until the whole process of the drug release is done by the targeted cancer cell.

Report Scope

Regional Analysis

• North America to dominate the global market during the coming period.

North America is expected to witness significant growth in the global antibody-drug conjugate market in the coming years due to the high prevalence of cancer incidences in the region. Moreover, the need for more effective and targeted treatment in the region is further widening the scope of the market.

Also, the FDA has approved many crucial ADCs for the treatment of cancer. These approvals and the fast expansion of biotech technology and the pharmaceutical industry are also contributing heavily to the growth of the regional market. Moreover, these drugs are also used in clinical trials. As a result, these drugs are showing a positive impact on cancer treatment, which in turn is also likely to accentuate the demand in the region.

The market in the Asia Pacific region is anticipated to see huge growth during the forecast period because of the growing aging population and surging awareness among patients regarding the successful treatment of cancer. Companies are collaborating with research institutions and local partners to expand their presence in that region.

The pharmaceutical and biotechnology companies are boosting their interest in the region because of its high potential and availability of an abundance of sources. However, these domestic and international companies are conducting their clinical trials for ADC in the region because of the presence of a diverse patient population for clinical research and huge opportunities under a cost-effective budget.

For instance, Gilead Sciences, Inc. got approval from the European Commission for sacituzumab govitecan as a monotherapy for the treatment of metastatic hormone receptor (HR)-positive in adult patients.

Competitive Analysis

The key players in the global antibody-drug conjugate (ADC) market include:

• Seattle Genetics
• Genentech
• Takeda Pharmaceuticals
• AstraZeneca
• Immunomedics
• Pfizer
• Daiichi Sankyo
• Mersana Therapeutics
• Synthon
• ADC Therapeutics
• MacroGenics
• Innovent Biologics
• Zymeworks
• Molecular Templates

For instance, AstraZeneca entered into a licensing agreement with KYM Biosciences in March 2023 for CMG-901. It basically targets Claudin 18.2 in the phase 1 clinical trial currently.

The global antibody-drug conjugate (ADC) market is segmented as follows:

By End Users Segment Analysis

• Biotechnology & Pharmaceutical Companies
• Hospitals & Specialty Cancer Centers
• Others

By Products Segment Analysis

• Kadcyla
• Adcetris
• Others

By Applications Segment Analysis

• Brain Tumors
• Skin Cancer
• Lung Cancer
• Ovary Cancer
• Breast Cancer
• Blood Cancer
• Others

By Target Types Segment Analysis

• HER2 Antibodies
• CD30 Antibodies
• Others

By Technology Segment Analysis

• Non-Cleavable Linkers
• Cleavable Linkers

By Regional Segment Analysis

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America